Tango Therapeutics, Inc. (TNGX) SEC Filings & Earnings Calls

Dependence on third-party supply of daraxonrasib for planned Phase 3 trial; potential regulatory delays or safety/efficacy issues.

“Expectations around securing sufficient clinical supply of daraxonrasib for planned Phase 3 trial.”

Clinical-stage biotech with no approved products; dependency on vopimetostat success

“Company is clinical-stage; vopimetostat is lead candidate; no approved products.”

Net loss increasing; G&A expenses doubled year-over-year

“Net loss $55.3M vs $38.9M prior year; G&A $22.6M vs $11.3M.”

Potential dilution from new $400M ATM offering (see separate filing)

“Company filed a new ATM offering of up to $400M on the same date.”

No approved products; pre-revenue

“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word

Clinical trial risk; combination data early stage

“The vopimetostat plus daraxonrasib combination was generally well-tolerated across dose levels. Most adverse events were grade one or two in severity.” · word for word

Program discontinuation risk

“Due to an increased focus on our PRMT5 pipeline, we are deprioritizing future development and resources allocated to TNG260 and are in the process of shutting down the clinical trial.” · word for word

Significant dilution risk from new $400M ATM offering

“New ATM offering of up to $400M, replacing prior $100M program; $64.4M already sold.”

Leadership transition at executive chair level; potential disruption to strategic direction.

“Departure of Executive Chair; no disagreement cited but loss of senior leadership.”

Dilution to existing shareholders from 20M share issuance (including pre-funded warrants).

“Offering of 18,166,667 shares plus 1,833,395 pre-funded warrant shares.”

Forward-looking statements caution that benefits may not be seen in later trials or broader populations; regulatory and funding risks.

“Risks include: benefits may not be evident in later trials; updated results may differ materially; regulatory developments; ability to fund operations.”

Resignations not due to disagreements, but board turnover could signal underlying issues; no immediate risk evident.

“Resignations were not a result of any disagreement with the Company on any matter relating to operations, practices or policies.”

No approved products; no revenue from product sales

“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word

Significant operating losses and accumulated deficit

“Since inception, we have incurred significant operating losses. For the three months ended March 31, 2026 and 2025, our net losses were $45.5 million and $39.9 million, respectively.” · word for word

Dependence on future financing

“We will need substantial additional funding to support our continuing operations and pursue our growth strategy.” · word for word

Clinical trial failure risk

“We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates.” · word for word

CFO departure may indicate internal issues, but separation terms are standard; no disagreement disclosed.

“Previously announced departure; separation agreement includes standard severance and release.”

CFO turnover may create uncertainty, but new appointment with experienced executive mitigates risk.

“Former CFO departed; new CFO has prior CFO experience at biotech companies.”

Clinical trial risk; vopimetostat pivotal study initiation in 2026.

“Pivotal study in 2L pancreatic cancer anticipated in 2026.”

Clinical trial failure risk

“we announced that we were discontinuing development of our TNG348 program due to liver toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial” · word for word

Capital need risk

“We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.” · word for word

No product revenue risk

“We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future.” · word for word

Potential dilution from $100M ATM offering; ongoing capital needs for clinical-stage biotech.

“the Company may sell up to an aggregate of $100,000,000 of shares of its common stock” · word for word

No approved products or revenue from product sales

“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word

History of operating losses

“Since inception, we have incurred significant operating losses. For the nine months ended September 30, 2025 and 2024, our net losses were $62.8 million and $92.6 million, respectively.” · word for word

Clinical trial uncertainty

“The successful development of our product candidates is highly uncertain.” · word for word

Clinical trial risk; vopimetostat pivotal study not yet started

“Planned pivotal trial in 2L MTAP-del pancreatic cancer with an anticipated study start in 2026” · word for word

Revenue concentration from Gilead collaboration truncation

“All remaining deferred revenue from the upfront and research option-extension payments under the Gilead collaboration were recognized as collaboration revenue during the three months ended September 30, 2025 as a result of the truncation of the collaboration agreement” · word for word

Dilution risk from equity offering; no specific amount disclosed.

“Issuance of common stock and pre-funded warrants in registered direct offering and private placement.”